X
[{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Relation Therapeutics Teams up With Mila in Coalition to Identify Covid-19 Therapeutic Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Relation Therapeutics"},{"orgOrder":0,"company":"Storm Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Storm Therapeutics"},{"orgOrder":0,"company":"Glox Therapeutics","sponsor":"Boehringer Ingelheim Venture Fund","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Glox Therapeutics Secures \u00a34.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Glox Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
The Company will use the funding to accelerate its bacteriocin development programme utilising engineered protein bacteriocins, which exhibit remarkable potency and specificity, enabling them to effectively and selectively target Gram-negative pathogens.
Lead Product(s):
Engineered Protein Bacteriocin
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Boehringer Ingelheim Venture Fund
Deal Size: $5.4 million
Upfront Cash: Undisclosed
Deal Type: Financing
November 13, 2023
Details:
The Innovate UK grant will allow STORM to develop a drug acting on a key coronavirus protein that is not targeted by current treatments. Generation of such a drug will provide a valuable option for treating Covid-19 and other coronavirus diseases.
Lead Product(s):
Undisclosed
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Innovate Biopharmaceuticals
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Funding
May 03, 2022
Details:
Project RE will focus on finding therapies to tackle viral entry and replication and is co-led between Mila (Quebec AI Institute) and Relation Therapeutics.
Lead Product(s):
Undisclosed
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Bill & Melinda Gates Foundation
Deal Size: $1.3 million
Upfront Cash: Undisclosed
Deal Type: Funding
September 01, 2020